Patent Expiry

Patent/Exclusivity Expiry: IMKELDI

Other upcoming events for IKT

Phase 3 ReadoutPhase 3 Topline: An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and
Phase 3 ReadoutPhase 3 Topline: Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability of IKT-001 in Pulmonar

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: IMKELDI — IKT Patent Expiry | BioSniper